Bolch, E.
Duke Medical Center
2 papers on CoChat
Most cited papers
- Verified
BACCI: A phase II randomized, double-blind, multicenter, placebo-controlled study of capecitabine (C) bevacizumab (B) plus atezolizumab (A) or placebo (P) in refractory metastatic colorectal cancer (mCRC): An ACCRU network study
Mettu, N. B., Twohy, E., Ou, F.-S., Halfdanarson, T. R., Lenz, H. J., Breakstone, R., Boland, P. M., Crysler, O., Wu, C., Grothey, A., et al. (2019) · Annals of Oncology
Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers
Cited by 72
- Verified
A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial)
Clarke, J. M., Blobe, G. C., Strickler, J. H., Uronis, H. E., Zafar, S. Y., Morse, M., Dropkin, E., Howard, L., O’Neill, M., Rushing, C. N., et al. (2019) · Cancer Chemotherapy and Pharmacology
Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments
Cited by 18
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free